

Q4 2022


YEAR-END REPORT

SEK 229.5 million

The Group's net sales increased to SEK 229.5 (184.2) million in the fourth quarter of 2022

SEK 17.6 million

The Group's operating profit decreased to SEK 17.6 (25.3) million in the fourth quarter of 2022



Q4 2022 YEAR-END REPORT

October – December 2022

- Net sales for the fourth quarter amounted to SEK 229.5 (184.2) million, an increase of 24.6 percent compared to the same quarter last year. Net sales in local currencies increased by 13.8 percent.
- Operating profit amounted to SEK 17.6 (25.3) million, corresponding to an operating margin of 7.7 (13.7) percent.
- Profit after net financial items amounted to SEK 1.4 (24.8) million. Net financial items were negatively affected by exchange rates of SEK -8.3 (1.2) million and totaled SEK -16.3 (-0.5) million.
- Profit after tax amounted to SEK 0.4 (19.5) million.
- Cash flow from operating activities was SEK 18.3 (33.4) million, and SEK -10.7 (5.5) million after investments.
- Earnings per share amounted to SEK 0.06 (2.42).

January – December 2022

- Net sales for the year amounted to SEK 888.5 (723.6) million, an increase of 22.8 percent compared to last year. Net sales in local currencies increased by 13.5 percent.
- Operating profit amounted to SEK 122.4 (101.1) million, corresponding to an operating margin of 13.8 (14.0) percent. Operating profit in the previous year includes a charge of SEK 15.6 million costs in connection with the completion of the offer from the new majority shareholder.
- Profit after net financial items amounted to SEK 99.1 (98.0) million. Net financial items were negatively affected by exchange rates of SEK -9.2 (4.2) million and totaled SEK -23.3 (-3.1) million.
- Profit after tax amounted to SEK 75.1 (75.6) million.
- Cash flow from operating activities was SEK 108.3 (105.0) million, and SEK -9.0 (19.6) million after investments.
- Earnings per share amounted to SEK 9.30 (9.37).

Dividend

- The Board of Directors proposes that no dividend be paid for the 2022 financial year and that retained earnings be carried forward.

Key performance indicators	Oct-Dec 2022	Oct-Dec 2021	Jan-Dec 2022	Jan-Dec 2021
Net sales, SEK million	229.5	184.2	888.5	723.6
Growth, %	24.6	19.0	22.8	24.8
Operating profit before depreciation and amortization (EBITDA), SEK million	36.1	39.6	189.1	156.6
Operating profit before depreciation and amortization (EBITDA), %	15.7	21.5	21.3	21.6
Operating profit (EBIT), SEK million	17.6	25.3	122.4	101.1
Operating profit (EBIT), %	7.7	13.7	13.8	14.0
Profit after financial items, SEK million	1.4	24.8	99.1	98.0
Undiluted and diluted earnings per share, SEK	0.06	2.42	9.30	9.37
Cash flow from operating activities, SEK million	18.3	33.4	108.3	105.0
Net debt, SEK million			277.5	261.3

THE GROUP'S PERFORMANCE

Net sales October-December 2022

The Group's net sales for the quarter increased to SEK 229.5 (184.2) million. The increase of 24.6 percent compared with the fourth quarter of last year is attributable to all business areas: Dental 1.5 percent, Orthopedics 72.5 percent and Life Science 7.9 percent. Sales of proprietary products in Dental business area grew 11.6 percent and accounted for 15.2 (16.9) percent of total consolidated net sales. Net sales in local currencies increased by 13.8 percent. All business areas have been positively affected by currency translation. For Orthopedics, the impact in the quarter is significant, where 27 percentage points of the growth comes from currency translation. Adjusted for currency translation, Dental reported a negative growth of 4.5 percent.

Net sales January-December 2022

The Group's net sales for the year increased to SEK 888.5 (723.6) million. The increase of 22.8 percent compared to last year is attributable to all business areas: Dental 9.5 percent, Orthopedics 43.3 percent and Life Science 17.2 percent. Sales of proprietary products in Dental business area grew 33.9 percent and accounted for 16.6 (15.2) percent of total consolidated net sales. Net sales in local currencies increased by 13.5 percent. All business areas have been positively affected by currency translation. For Orthopedics, the impact for the period is significant, where 19 percentage points of the growth comes from currency translation.

Earnings October-December 2022

The operating profit for the fourth quarter amounted to SEK 17.6 (25.3) million, corresponding to an operating margin of 7.7 (13.7) percent. Adjusted for currency prior year's operating profit would have been SEK 30 million. In the previous year, operating profit was negatively affected by SEK 4 million attributable to a strategic review. Other operating income previous year included SEK 2.0 million related to repayment of AGS premiums for 2004-2008. The Group's net financial items were affected by exchange rate, mainly in relation to revaluation of loans, of SEK -8.3 (1.2) million and by a revaluation of interest rate swap, of SEK -0.1 (0.6) million. Net financial items amounted to SEK -16.3 (-0.5) million. Earnings after financial items amounted to SEK 1.4 (24.8) million and earnings after tax amounted to SEK 0.4 (19.5) million.

Earnings per share October-December 2022

Fourth quarter earnings per share both before and after dilution were SEK 0.06 (2.42) per share.

Earnings January-December 2022

The operating profit for the year amounted to SEK 122.4 (101.1) million, corresponding to an operating margin of 13.8 (14.0) percent. Adjusted for currency prior year's operating profit would have been SEK 111 million. Operating profit in the previous year includes a charge of SEK 19.6 million related to transaction costs in connection with the completion of the offer from the new majority owner and strategic review. Previous year's other operating income included SEK 2.0 million related to repayment of AGS premiums for 2004-2008. The Group's net financial items were affected by exchange rate, mainly in relation to revaluation of loans, of SEK -9.2 (4.2) million and by a revaluation of interest rate swap, of SEK 6.0 (2.7) million. Net financial items amounted to SEK -23.3 (-3.1) million. Earnings after financial items amounted to SEK 99.1 (98.0) million and earnings after tax amounted to SEK 75.1 (75.6) million.

Earnings per share January-December 2022

Earnings per share both before and after dilution for the year were SEK 9.30 (9.37) per share.

Investments

The Group's investments for the fourth quarter amounted to SEK 29.1 (27.9) million and mainly relate to investments in machinery and property for a couple of the Group's sites, in order to expand production capacity and to continue to meet the demand from the Group's customers. In total for the year investments of SEK 117.2 (85.5) million.

Financial position and liquidity

Consolidated total assets increased during the period to SEK 1,422.9 (1,126.4) million. Equity increased by SEK 164.1 million over the period with translation of foreign subsidiaries accounting for SEK 41.8 million of the increase. Total equity amounted to SEK 798.5 (634.4) million. Equity per share, calculated on 8,068,000 shares, amounted to SEK 99.0 (78.6). At the end of the year, riskbearing capital was SEK 844.8 (663.3) million, which corresponds to 59.4 (58.9) percent of total capital. The Group's equity ratio was 56.1 (56.3) percent.

Cash flow

The Group's cash flow from operating activities for the quarter amounted to SEK 18.3 (33.4) million. Operating cash flow in the quarter amounted to SEK -10.7 (5.5) million. The Group's cash flow from operating activities for the year amounted to SEK 108.3 (105.0) million and operating cash flow amounted to SEK -9.0 (19.6) million. The Group's net debt increased during the period, to SEK 277.5 (261.3) million. The Group's cash and cash equivalents amounted to SEK 168.7 (95.1) million.

Personnel

The average number of employees in the Group for the fourth quarter was 661 compared to 553 in the previous year, which is an increase of 19.5 percent. The average number of employees in the Group for the year was 626 compared to 535 from the previous year, which is an increase of 17.0 percent. At the end of the period, the number of employees in the Group was 666 (562).

Events during the quarter

No events to report during the quarter.

Events after the end of the quarter

The Board of Directors has updated the company's dividend policy to adapt the dividend to the company's increased investment needs.

The new dividend policy reads:

Elos Medtech's dividend policy is that the dividend should be based on the Group's profit development, considering future development opportunities and the financial position. The Board's assessment is that any surplus funds in the coming years will need to be reinvested in the business, to cover the company's investment needs.

OTHER INFORMATION

Accounting policies

This interim report has been prepared in accordance with IAS 34 Interim Reporting and the relevant provisions of the Annual Accounts Act. The interim report of the Parent Company has been prepared in accordance with Chapter 9 of the Annual Accounts Act, Interim Report. For the Group and the Parent Company, the same accounting principles and calculation bases have been applied as in the most recent annual report.

In addition to the financial statements, disclosures in accordance with IAS 34.16A are also presented in parts of the interim report.

Segment reporting

The internal financial follow-up per business area is adapted to the Group's various customer segments and uses operating profit as a measure to assess segment performance. Directly attributable items and items that can reasonably be allocated by segment have been included in the segment's operating profit.

Unallocated Group expenses refer mainly to note-related costs.

Financial instruments at fair value

For the property loans in the US, the Group swaps its variable interest rate for a fixed rate through interest rate swaps. These interest rate swaps are recognized at fair value via the income statement. Unrealized gains and losses arising from fluctuations in the fair values of the financial instruments are recognized in net financial items in the consolidated income statement. For interest rate swaps, fair value is determined based on market prices. If such prices are not available, fair value is determined by discounting the difference between the contractual interest rate and the interest rate that can be obtained at the balance sheet date for the remaining contract term. Any premiums paid for the swap contract are recognized as interest over the term of the contract. As Elos Medtech intends to hold these derivatives to maturity, mark-to-market accounting of the derivatives over time will not affect earnings or cash flow.

Fair value measurement of interest rate derivatives had a negative impact on quarterly earnings of SEK -0.1 (0.6) million, and a positive impact of SEK 6.0 (2.7) million on earnings for the first nine months of the year.

Significant risks and uncertainties

The Group's principal risks and uncertainties include operational and financial risks. Among operational risks, Elos Medtech is primarily affected by risks associated with customers and markets, but also other external factors such as price risks for materials and supplies. The Group also faces financial risks associated with changes in exchange rates and credit risks. A detailed description of the Group's risks and uncertainties, as well as how these are being managed, is provided in the Directors' Report and in Notes 42 and 44 in the 2021 Annual Report.

Related party transactions

The company had no transactions with related parties during the reporting period.

Parent Company

In addition to the administration of central management issues, the parent company also provide Group-wide support in IT and marketing, quality management, risk management, financing, and financial control.

The Parent Company's net sales in the fourth quarter amounted to SEK 7.6 (4.8) million. Profit after financial items amounted to SEK -39.8 (22.4) million, of which SEK -32.3 (4.8) million refers to negative exchange rate differences mainly related to the translation effect of USD loans to subsidiaries and net translation effect of internal and external loans in EUR. The result was negatively affected by SEK 2.2 million due to changed basis of calculation for the PRI pension liability. SEK 1.4 million of this change has been reported as increased financial expenses. The Parent Company reported a profit after tax of SEK -31.9 (16.2) million.

The Parent Company's net sales for the year amounted to SEK 29.6 (24.3) million. Profit after financial items amounted to SEK 19.5 (32.9) million, of which SEK 23.2 (16.2) million refers to exchange rate differences mainly related to the translation of loans to subsidiaries. The Parent Company reported a profit after tax of SEK 18.8 (27.6) million. The percentage of risk-bearing capital was 53.8 (80.6) percent. The equity ratio was 53.6 (80.3) percent.

Future-oriented information

The company does not make forecasts.

Future-oriented information in this report is based on management's expectations at the time of the report. Although the Board of Directors and management feel that these expectations are reasonable, it is no guarantee that the expectations are, or will prove to be, correct. Consequently, future outcomes may vary significantly compared to the future-oriented information due to such things as changes in the market conditions for the Group's services or changes in the overall situation concerning the economy, market and competition, changes in legal requirements and other policy measures as well as fluctuations in exchange rates. The company does not undertake to update or correct any future-oriented information except as stipulated by law.

Proposed appropriation of retained earnings

According to the dividend policy of Elos Medtech AB (publ), the dividend shall be based on the Group's earnings performance, taking into account future development potential and financial position. The Board's assessment is that any surplus funds in the coming years will need to be reinvested in the business, to cover the company's investment needs. The Board proposes, in accordance with existing policy, that no dividend be paid for 2022.

Examination by the auditors

This report has not been subjected to a review by the company's auditors.

Gothenburg, February 23, 2023

Elos Medtech AB (publ)

The Board of Directors

CONDENSED CONSOLIDATED INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

SEK million		Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Income statement		2022	2021	2022	2021
Net sales		229.5	184.2	888.5	723.6
Cost of goods sold		-163.0	-121.4	-578.1	-468.1
Gross profit		66.6	62.8	310.4	255.5
Selling expenses		-12.1	-9.6	-47.6	-35.6
Administrative expenses		-30.6	-25.2	-118.3	-103.1
Development costs		-5.8	-5.1	-24.4	-17.7
Other operating income/expenses		-0.4	2.4	2.4	2.0
Operating profit		17.6	25.3	122.4	101.1
Financial income		0.7	2.2	11.9	7.8
Financial expenses		-17.0	-2.7	-35.2	-10.9
Profit after financial items		1.4	24.8	99.1	98.0
Tax expense		-1.0	-5.2	-24.1	-22.4
Profit after tax		0.4	19.5	75.1	75.6
Attributable to Parent Company shareholders		0.4	19.5	75.1	75.6
Undiluted and diluted earnings per share, SEK*		0.06	2.42	9.30	9.37
* Attributable to Parent Company shareholders' share of profit after tax.					
Statement of comprehensive income					
Profit after tax		0.4	19.5	75.1	75.6
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Actuarial gains and losses		15.6	-6.4	26.8	-3.5
Tax		-3.2	1.3	-5.5	0.7
		12.4	-5.1	21.3	-2.8
Items that may be reclassified to profit or loss					
Translation differences for the period		-33.3	11.3	74.4	36.4
Tax		4.9	-0.8	-6.7	-2.7
		-28.3	10.5	67.7	33.7
Other comprehensive income. net		-16.0	5.5	89.0	30.9
Comprehensive income for the year		-15.6	25.0	164.1	106.5
Parent Company shareholders		-15.6	25.0	164.1	106.5
Operating profit before depreciation and amortization (EBITDA)	%	15.7	21.5	21.3	21.6
Operating profit (EBIT)	%	7.7	13.7	13.8	14.0
Depreciation and amortization charged to earnings	SEK million	18.5	14.3	66.7	55.5

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEK million

Balance sheet	31 Dec 2022	31 Dec 2021
Assets		
Intangible assets	309.6	272.3
Property, plant and equipment	562.4	469.5
Financial fixed assets	0.1	1.4
Current assets	382.1	288.1
Cash and cash equivalents	168.7	95.1
Total assets	1 422.9	1 126.4
Equity and liabilities		
Equity	798.5	634.4
Non-current liabilities	469.0	316.6
Current liabilities	155.4	175.4
Total equity and liabilities	1 422.9	1 126.4

CONDENSED CONSOLIDATED CASH FLOWS STATEMENT

SEK million	Oct-Dec 2022	Oct-Dec 2021	Jan-Dec 2022	Jan-Dec 2021
Cash flow				
Profit after net financial items	1.4	24.8	99.1	98.0
Reversal of depreciation and amortization	18.5	14.3	66.7	55.5
Adjustment for non-cash items	10.4	1.2	8.6	-2.1
Tax paid	-3.7	-10.8	-11.5	-18.2
Changes in working capital	-8.3	3.9	-54.6	-28.2
Cash flow from operating activities	18.3	33.4	108.3	105.0
Investments in fixed assets	-29.1	-27.9	-117.2	-85.5
Sale of fixed assets	-	-	-	0.1
Cash flow from investing activities	-29.1	-27.9	-117.2	-85.4
Operating cash flow	-10.7	5.5	-9.0	19.6
Borrowings	3.2	12.5	343.6	60.9
Repayment of borrowings	-5.4	-25.6	-269.6	-67.8
Dividend to shareholders	-	-	-	-12.1
Cash flow from financing activities	-2.2	-13.1	74.0	-19.0
Cash flow for the period	-12.9	-7.6	65.0	0.5
Cash and cash equivalents at the beginning of the period	188.0	101.5	95.1	88.5
Exchange rate difference in cash and cash equivalents	-6.4	1.2	8.5	6.1
Cash and cash equivalents at the end of the period	168.7	95.1	168.7	95.1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

SEK million	31 Dec 2022	31 Dec 2021
Opening balance	634.4	540.3
Total comprehensive income	164.1	106.2
Dividend	-	-12.1
Closing equity	798.5	634.4

KEY PERFORMANCE INDICATORS, GROUP

		Jan-Dec 2022	Jan-Dec 2021
Return on operating capital	%	12.4	12.0
Return on equity	%	10.5	12.9
Share of risk-bearing capital	%	59.4	58.9
Equity ratio	%	56.1	56.3
Net debt/EBITDA	times	1.5	1.7
Investments, not including acquisitions	SEK million	117.2	85.5
Average number of employees	number	626	535

DATA PER SHARE

		Jan-Dec 2022	Jan-Dec 2021
Undiluted and diluted earnings per share, SEK*	SEK million	9.30	9.37
Average number of shares	thousands	8,068.0	8,068.0
Number of shares at the end of the period	thousands	8,068.0	8,068.0
Equity per share	SEK	99.0	78.6
Share price at the end of the period	SEK	246.0	274.0
Dividend**	SEK	-	-

* Attributable to Parent Company shareholders' share of profit after tax

** The Board of Directors proposes that no dividend be paid for the 2022 financial year

BUSINESS AREA INFORMATION

SEK million			Growth		Growth	
	Oct-Dec 2022	Oct-Dec 2021	Oct-Dec 2022	Jan-Dec 2022	Jan-Dec 2021	Jan-Dec 2022
Net sales by business area						
Dental	70.4	69.3	1.5%	302.1	275.8	9.5%
Orthopedics	93.9	54.4	72.5%	338.7	236.3	43.3%
Life Science	65.2	60.4	7.9%	247.8	211.4	17.2%
Total net sales	229.5	184.2	24.6%	888.5	723.6	22.8%

The value of sales between business areas is minor.

SEK million	Oct-Dec 2022	Oct-Dec 2021	Jan-Dec 2022	Jan-Dec 2021
EBITDA by business area				
Dental	12.8	15.2	73.6	67.8
Orthopedics	12.2	10.4	53.2	53.2
Life Science	12.8	16.2	67.9	56.7
Unallocated Group expenses	-1.7	-2.4	-5.8	-21.3
Total profit before depreciation and amortization	36.1	39.4	188.9	156.5
Depreciation and amortization by business area				
Dental	-5.1	-4.0	-19.7	-17.6
Orthopedics	-8.2	-4.8	-27.4	-19.1
Life Science	-5.2	-5.1	-19.5	-18.5
Total depreciation and amortization	-18.5	-14.0	-66.7	-55.5
Operating profit by business area				
Dental	7.8	11.1	54.0	50.2
Orthopedics	3.9	5.5	25.8	34.1
Life Science	7.7	11.1	48.4	38.2
Unallocated Group expenses	-1.7	-2.4	-5.8	-21.3
Total operating profit	17.6	25.3	122.4	101.1

QUARTERLY RESULTS FOR THE GROUP

SEK million	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Quarterly results								
Net sales	229.5	231.5	233.1	194.5	184.2	187.2	181.0	171.2
Cost of goods sold	-163.0	-147.0	-147.2	-120.9	-121.4	-119.1	-115.6	-112.0
Gross profit	66.5	84.5	85.9	73.5	62.8	68.1	65.4	59.2
Sales, admin and development costs	-48.5	-47.8	-49.6	-44.4	-39.9	-43.6	-39.2	-33.8
Other operating income and expenses	-0.4	1.1	1.5	0.2	2.4	-0.3	0.3	-0.4
Operating profit	17.6	37.7	37.8	29.2	25.3	24.2	26.5	25.0
Financial income	0.7	2.3	5.3	3.6	2.2	1.8	-	4.9
Financial expenses	-17.0	-11.0	-4.2	-3.0	-2.7	-2.7	-3.7	-2.8
Profit after financial items	1.4	29.0	38.8	29.8	24.8	23.3	22.8	27.1
Tax expense	-1.0	-7.2	-9.1	-6.8	-5.2	-5.7	-4.4	-7.1
Profit after tax	0.4	21.9	29.7	23.0	19.5	17.6	18.4	20.0

PARENT COMPANY INCOME STATEMENT

SEK million	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Income statement	2022	2021	2022	2021
Net sales	7.6	4.8	29.6	24.3
Selling expenses	-1.3	-2.1	-7.7	-8.0
Administrative expenses	-12.3	-11.1	-43.6	-46.6
Other operating income/expenses	-0.1	-	-	-0.1
Operating profit	-6.1	-8.4	-21.7	-30.4
Income from investments in Group companies	-	25.0	19.4	44.0
Interest income, Group companies	5.3	1.2	14.1	4.5
Other interest income and similar income	0.1	4.8	55.9	16.2
Other interest expense and similar charges	-39.2	-0.2	-48.2	-1.4
Profit after financial items	-39.8	22.4	19.5	32.9
Appropriations	-0.3	-2.0	-0.3	-2.8
Tax on profit for the year	8.2	-4.2	-0.4	-2.5
Profit after tax	-31.9	16.2	18.8	27.6

* Profit after tax is the same as comprehensive income for the year.

CONDENSED PARENT COMPANY BALANCE SHEET

SEK million	31 Dec 2022	31 Dec 2021
Balance sheet		
Assets		
Intangible assets	2.5	3.3
Property, plant and equipment	0.2	0.2
Financial fixed assets	677.1	412.8
Current assets	50.3	62.5
Cash and cash equivalents	63.2	26.9
Total assets	793.3	505.7
Equity and liabilities		
Equity	419.3	400.5
Untaxed reserves	7.2	7.0
Provisions for pensions	11.1	8.5
Non-current liabilities	313.7	17.2
Current liabilities	42.0	72.5
Total equity and liabilities	793.3	505.7

RECONCILIATION BASIS FOR ALTERNATIVE PERFORMANCE MEASURE

The interim report presents certain financial performance measures of earnings trend, financial position and cash flow that are not defined in accordance with IFRS. These performance measures are intended to serve as important supplementary performance indicators of the Group's performance and financial position and the purpose is to provide a better understanding of the business. Elos Medtech's definitions of these measures may differ from other companies' definitions of the same concepts. The alternative performance measures presented in the interim reports should not be regarded as a replacement to terms and concepts in accordance with IFRS. They are instead intended as a supplement.

Calculations of non-IFRS performance measures that are not mentioned elsewhere in the interim report are presented below. For complete information regarding the calculation and reasons for using alternative performance measures, please see: www.elosmedtech.com.

SEK million	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Growth	2022	2021	2022	2021
Reported net sales	229.5	184.2	888.5	723.6
Net sales for the corresponding period last year	184.2	154.8	723.6	580.0
Change in net sales	45.3	29.4	164.9	143.6
Growth, %	24.6	19.0	22.8	24.8
Net sales adjusted for exchange rate changes				
Exchange rate changes	17.5	1.7	59.5	-15.0
Net sales for the corresponding period last year adjusted for exchange rate changes	201.7	156.5	783.1	565.0
Growth adjusted for exchange rate changes, %	13.8	17.7	13.5	28.2
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
EBITDA	2022	2021	2022	2021
Reported operating profit	17.6	25.3	122.4	101.1
Depreciation/amortization	18.5	14.3	66.7	55.5
EBITDA	36.1	39.6	189.1	156.6
Risk-bearing capital			31 Dec 2022	31 Dec 2021
Equity			798.5	634.4
Deferred tax liability			46.3	28.9
Risk-bearing capital			844.8	663.3
Net debt			31 Dec 2022	31 Dec 2021
Non-current interest-bearing provisions for pensions			45.8	69.9
Non-current interest-bearing liabilities			376.9	217.2
Current interest-bearing liabilities			23.5	69.3
Total liabilities			446.2	356.4
Cash and cash equivalents			-168.7	-95.1
Net debt			277.5	261.3
Liquidity reserve			31 Dec 2022	31 Dec 2022
Cash and cash equivalents			168.7	95.1
Revolving Credit facility			111.3	-
Liquidity reserve			280.0	95.1

Financial calendar

<u>Activity</u>	<u>Date</u>
Annual Report 2022	12 April 2023
Interim Report January-March 2023	April 26, 2023
Interim Report January-June 2023	July 14, 2023
Interim Report January-September 2023	October 19, 2023
Year-End Report 2023	February 22, 2024

Annual General Meeting 2023

The Annual General Meeting 2023 will be held on May 3, 2023. Further information will be released in the notice convening the Annual General Meeting.

Annual Report and Sustainability Report 2022

Elos Medtech's Annual Report and Sustainability Report for 2022 are expected to be available on April 12, 2023, when these are published on the company's website www.elosmedtech.com.

Publication

This information in this report is information that Elos Medtech AB (publ) is required to publish under the EU Market Abuse Regulation. The information was submitted (by the contact person specified below) for publication on February 23 at 08:00 a.m. (CET).

Elos Medtech AB (publ) is a Swedish limited liability company, whose B shares are listed on Mid Cap, NASDAQ Stockholm AB. Elos Medtech's corporate governance is based on Swedish legislation and the company's listing agreement with NASDAQ Stockholm AB.

This is a translation of the Swedish version of the Year-End Report 2022. When in doubt, the Swedish wording prevails.

.....

For questions about the report, please contact:



Stefano Alfonsi
President and CEO
Mob: +44 772 04 98 342
Email: stefano.alfonsi@elosmedtech.com



Ewa Linsäter
Chief Financial Officer
Mob: +46 766 33 32 33
Email: ewa.linsater@elosmedtech.com

FIND US HERE



Elos Medtech AB (publ)

Torsgatan 5B
SE-411 04 Gothenburg
Sweden
Tel: +46 10 171 20 00
Corp. ID no: 556021-9650
info@elosmedtech.com
www.elosmedtech.com

